Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.50 from $5 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals Balances Early Wins and Runway
- Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)
- Recursion Highlights Q1 2026 Results and Pipeline Progress
- Recursion Pharmaceuticals Announces Planned Board Leadership Transition
- Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan